Inhibrx Biosciences, Inc. — Investor Relations & Filings
Filings indexed
115
across all filing types
Latest filing
2026-04-23
Annual Report
Country
US
United States of America
Listing
US
INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel biologic therapeutics for patients with life-threatening conditions. The company leverages its expertise in protein engineering and an understanding of target biology to advance a pipeline of therapeutic candidates. Its clinical programs are focused on oncology, with lead trials covering cancers such as sarcoma, chondrosarcoma, and head and neck cancer. A key candidate in its pipeline is ozekibart (INBRX-109), a tetravalent DR5 agonist. Inhibrx combines deep scientific and clinical experience with an agile and innovative approach to address unmet medical needs in biotherapeutics.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-04-23 | English | |
| DEF 14A - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-04-23 | English | |
| 8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-04-21 | English | |
| 8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-03-19 | English | |
| 10-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-03-19 | English | |
| 8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-02-23 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 35871681 | ARS - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-04-23 | English | ||
| 35868221 | DEF 14A - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-04-23 | English | ||
| 34907862 | 8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-04-21 | English | ||
| 32989153 | 8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-03-19 | English | ||
| 32989166 | 10-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-03-19 | English | ||
| 32827585 | 8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer) | 2026-02-23 | English | ||
| 32295214 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 13687073 | Major Shareholding Notification 2026 | 2026-01-21 | English | ||
|
2025
7 filings
| |||||
| 13687092 | 8-K | 2025-12-16 | English | ||
| 13687110 | 8-K | 2025-11-14 | English | ||
| 13687141 | 10-Q | 2025-11-13 | English | ||
| 13687153 | 8-K | 2025-10-23 | English | ||
| 13687154 | Major Shareholding Notification 2025 | 2025-10-18 | English | ||
| 13687157 | Director's Dealing 2025 | 2025-10-09 | English | ||
| 13687180 | 8-K | 2025-08-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Inhibrx Biosciences, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32884/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32884 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32884 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32884 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32884}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Inhibrx Biosciences, Inc. (id: 32884)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.